Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by K. Ijichi.
Archives of Virology | 1998
Masatoshi Fujiwara; Mika Okamoto; K. Ijichi; Kenji Tokuhisa; Yasuaki Hanasaki; Kimio Katsuura; Daisuke Uemura; Shiro Shigeta; Kenji Konno; Tomoyuki Yokota; Masanori Baba
SummaryWe have previously reported that ingenol derivatives are highly potent inhibitors of human immunodeficiency virus type 1 (HIV-1) replication in acutely infected cells. In this study, however, we have found that some ingenol derivatives strongly enhance the replication of HIV-1 in chronically infected cells at nanomolar concentrations. One of the derivatives could activate nuclear factor κB(NF-κB), a potent inducer of HIV-1 replication, through the activation of protein kinase C (PKC). Whereas another derivative, which affected neither PKC nor NF-κB, significantly enhanced HIV-1 replication, suggesting that a PKC-independent mechanism may also exist in ingenol derivative-induced HIV-1 upregulation.
Antiviral Research | 1996
K. Ijichi; Masatoshi Fujiwara; Hideki Nagano; Yukiharu Matsumoto; Yasuaki Hanasaki; Teruhiko Ide; Kimio Katsuura; Hiromitsu Takayama; Seiichiro Shirakawa; Norio Aimi; Shiro Shigeta; Kenji Konno; Masaaki Matsushima; Tomoyuki Yokota; Masanori Baba
The structure-activity relationship of the non-nucleoside HIV-1-specific reverse transcriptase (RT) inhibitors 4-phenyl-1,2,5-thiadiazol-3-yl N,N-dialkylcarbamate (TDA) derivatives was investigated with respect to their anti-HIV-1 activity, RT inhibition, and lipophilicity. 4-Phenyl-1,2,5-thiadiazol-3-yl N,N-dimethylcarbamate inhibited HIV-1-induced cytopathic effect (CPE) by 50% at a concentration of 28.8 microM in MT-4 cells. The activity increased more than 100-fold when the hydrogens at the 2-position and the 6-position in phenyl moiety were substituted by chlorines. However, the derivative with a chlorine at the 4-position of phenyl moiety did not show any inhibition of HIV-1 replication at its non-toxic concentrations. All of the 4-(2,6-dichlorophenyl)-1,2,5-thiadiazol-3-yl N-methyl-N-alkylcarbamates proved inhibitory to HIV-1 replication in the nanomolar concentration range. The TDA derivatives that showed anti-HIV-1 activity also inhibited RT activity in an enzymatic assay. However, the TDA derivatives did not show any specific inhibition of a non-nucleoside RT inhibitor (NNRTI)-resistant mutant and its RT activity. When the TDA derivatives were examined for their inhibitory effect on HIV-1 replication in the presence of 50% human serum, the activity significantly decreased depending on-their lipophilicity.
Bioorganic & Medicinal Chemistry Letters | 1996
Hiromitsu Takayama; Seiichiro Shirakawa; Mariko Kitajima; Norio Aimi; Kentaro Yamaguchi; Yasuaki Hanasaki; Teruhiko Ide; Kimio Katsuura; Masatoshi Fujiwara; K. Ijichi; Kenji Konno; Shiro Sigeta; Tomoyuki Yokota; Masanori Baba
Abstract The classical Wieland furoxan synthesis was reinvestigated and this procedure was applied to the preparation of 4-aryl-1,2,5-oxadiazole-3-yl N,N-dialkylcarbamate derivatives, which were found to exhibit potent anti-HIV-1 activity.
Antimicrobial Agents and Chemotherapy | 1996
Masatoshi Fujiwara; K. Ijichi; Kenji Tokuhisa; Kimio Katsuura; Shiro Shigeta; Kenji Konno; Gui-Yang-Sheng Wang; Daisuke Uemura; Tomoyuki Yokota; Masanori Baba
Journal of Medicinal Chemistry | 1995
Yasuaki Hanasaki; Hiroshi Watanabe; Kimio Katsuura; Hiromitsu Takayama; Seiichiro Shirakawa; Kentaro Yamaguchi; Shin-ichiro Sakai; K. Ijichi; Masatoshi Fujiwara; Kenji Konno
Antimicrobial Agents and Chemotherapy | 1995
K. Ijichi; Masatoshi Fujiwara; Y Hanasaki; H Watanabe; Kimio Katsuura; H Takayama; S Shirakawa; S Sakai; Shiro Shigeta; Kenji Konno
Antiviral Research | 1995
Masatoshi Fujiwara; K. Ijichi; Kenji Konno; Tomoyuki Yokota; Yasuaki Hanasaki; H. Watanabe; Kimio Katsuura; Seiichiro Shirakawa; Hiromitsu Takayama; S. Sakai; Shiro Shigeta; Masanori Baba
Antiviral Research | 1995
Masatoshi Fujiwara; K. Ijichi; Kenji Konno; Tomoyuki Yokota; K. Tokuhisa; Kimio Katsuura; D. Uemura; Shiro Shigeta; Masanori Baba
Antiviral Research | 1996
H. Nagano; K. Ijichi; Masatoshi Fujiwara; Yukiharu Matsumoto; Kenji Konno; Tomoyuki Yokota; M. Matsushima; Yasuaki Hanasaki; Kimio Katsuura; Hiromitsu Takayama; Norio Aimi; Masanori Baba; Shiro Shigeta
Antiviral Research | 1995
H. Nagano; K. Ijichi; Yukiharu Matsumoto; Masatoshi Fujiwara; Yasuaki Hanasaki; H. Watanabe; M. Katsuura; Seiichiro Shirakawa; Hiromitsu Takayama; S. Sakai; Shiro Shigeta; Kenji Konno; Masanori Baba; M. Matsushima; Tomoyuki Yokota